Streetbeat News

Revenues

AMP

Ameriprise Financial (NYSE:AMP) received mixed analyst ratings, with a recent shift towards more positive evaluations. The average 12-month price target was raised to $451.71, reflecting an 8.03% increase from the previous target. Analysts from firms like Argus Research, RBC Capital, and Goldman Sachs have raised their price targets, indicating a bullish outlook. Ameriprise, with $1.4 trillion in assets under management, shows strong revenue growth and ROE but faces challenges in net margin and ROA.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 5:00 pm

ETHUSD

SOLUSD

Joe McCann, founder of Asymmetric, expressed a bullish outlook on Solana (SOL), citing its high throughput, low transaction costs, and the upcoming 'Fire Dancer' update aimed at increasing transaction capacity. He compared Solana's potential impact on the crypto market to the role of meme coins and discussed the concept of 'financial nihilism' among younger generations. The discussion anticipates further exploration at the Benzinga Future of Digital Assets event.

Portfolio Pulse from Murtuza Merchant

May 06, 2024 | 4:20 pm

SBUX

Starbucks Corp (NASDAQ:SBUX) is experiencing a significant sales decline, with a deceleration pace in same-store sales rarely seen outside major economic crises, according to BofA Securities. Analyst Sara Senatore maintains a Buy rating on Starbucks, with a price target of $108, despite the sales slump. The decline is attributed to a social media narrative around Starbucks' position on the Middle East, rather than consumer check fatigue or pricing issues, as Starbucks' pricing remains competitive. The company's Net Promoter Score has also dropped sharply from October to November 2023.

Portfolio Pulse from Priya Nigam

May 06, 2024 | 4:02 pm

ATI

Analysts have recently updated their ratings and price targets for ATI (NYSE:ATI), showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has been raised to $63.5, indicating a 19.07% increase from the previous target. Key analysts from Barclays, Keybanc, and Deutsche Bank have adjusted their price targets and ratings, reflecting optimism about ATI's future performance. Despite facing challenges in debt management and asset utilization, ATI has shown solid revenue growth and impressive net margin and ROE figures.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 4:00 pm

FATE

Analysts have provided diverse opinions on Fate Therapeutics (NASDAQ:FATE), with recent ratings ranging from 'Somewhat Bullish' to 'Indifferent'. Over the past quarter, there has been a notable shift towards a more cautious stance, with the majority now holding an 'Indifferent' rating. The 12-month price targets for FATE have seen a significant increase, with the current average target at $7.25, up 81.25% from the previous $4.00. This change reflects adjustments in analysts' expectations, with several analysts raising their price targets. Despite the optimistic price target adjustments, Fate Therapeutics faces financial challenges, including a -96.22% decline in revenue growth and below-industry benchmarks in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 4:00 pm

AMD

NVDA

TSM

TSMC's advanced encapsulation capacity is fully booked by NVIDIA and AMD until next year, driven by high demand in the AI and High-Performance Computing (HPC) markets. TSMC anticipates server AI processor revenue to more than double this year, contributing to a significant portion of its total revenue. The company expects a 50% annual growth rate for server AI processors, projecting they will account for over 20% of TSMC's revenue by 2028.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 3:57 pm

SPY

The New York Fed reported expectations for home prices and rent in the U.S. to rise significantly. The year-ahead home price increase is forecasted at 5.1%, up from 2.6% in February 2023. The five-year-ahead home price expectation slightly decreased to 2.7% from 2.8%. Rent is expected to rise by 9.7% year-ahead, marking the second highest increase in survey history and up from 8.2% in February 2023. Additionally, renters' expectations for achieving home ownership have reached a record low.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 3:01 pm

HOWL

Werewolf Therapeutics (NASDAQ:HOWL) has been analyzed by 4 analysts, showing a mix of bullish and somewhat bullish ratings with no bearish sentiments. The average 12-month price target is $13.5, with a high of $15.00 and a low of $12.00, marking a 10% decline from the previous target. The company's financial health indicates a strong market presence but challenges in revenue growth, profitability, and asset utilization. Analysts' ratings and price targets reflect their perceptions and reactions to the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 3:01 pm

AEE

Ameren (NYSE:AEE) has received mixed analyst ratings over the past three months, with a recent shift towards more positive evaluations. Analysts have updated their price targets, reflecting an average increase to $75.83, up from $74.80. This change is based on Ameren's solid financial performance, including a 12.24% revenue growth and a net margin of 14.37%, despite its market capitalization and returns on equity and assets being below industry benchmarks. The company's debt management is noted as balanced, with a debt-to-equity ratio of 1.5.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 3:00 pm

PLMR

In the last three months, 10 analysts have updated their ratings on Palomar Holdings (NASDAQ:PLMR), showing a mix of bullish to indifferent sentiments. The average 12-month price target has been raised to $86.7, reflecting an 11.01% increase from the previous target. Analysts from firms like Piper Sandler, Truist Securities, and JP Morgan have adjusted their price targets and ratings, indicating a positive outlook on the company's performance. Palomar Holdings, specializing in specialty property insurance, has shown notable revenue growth and financial health, with a revenue growth rate of 12.47% and a net margin of 22.26%.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 3:00 pm